Drug Type Oncolytic virus |
Synonyms MV NIS, MVNIS, Sodium Iodide Simporter Measles Virus + [2] |
Target |
Mechanism NIS modulators(solute carrier family 5 member 5 modulators), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Vyriad, Inc.Startup |
Active Organization Vyriad, Inc.Startup |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fallopian Tube Carcinoma | Phase 2 | - | Vyriad, Inc.Startup | - |
Multiple Myeloma | Phase 2 | - | Vyriad, Inc.Startup | - |
Ovarian Cancer | Phase 2 | - | Vyriad, Inc.Startup | - |
Peritoneal Neoplasms | Phase 2 | - | Vyriad, Inc.Startup | - |
Breast Cancer | Phase 1 | - | Vyriad, Inc.Startup | - |
Mesothelioma | Phase 1 | - | Vyriad, Inc.Startup | - |
Rhabdomyosarcoma | Phase 1 | - | Vyriad, Inc.Startup | - |
Squamous Cell Carcinoma | Phase 1 | - | Vyriad, Inc.Startup | - |
Head and Neck Neoplasms | Preclinical | US | Vyriad, Inc.Startup | - |
Mesothelioma | Discovery | US | - | - |
Phase 1 | 2 | yvrdwbfzir(xrbfbresya) = tafuctqbkb zdylunknur (zrvmondsni, fzbsjmltlu - asibsxtosm) View more | - | 21 Jul 2023 | |||
Phase 1 | Transitional Cell Carcinoma Neoadjuvant | 8 | (tlgdxpdhpn) = Only a single Adverse Event (AE) attributable to MV-NIS treatment (Grade 1 hematuria) zsrhipvxpt (pljsywwdxl ) | Positive | 16 Feb 2022 | ||
Phase 2 | 2 | kiyvgvewlg(xilvbwnnay) = cwlpcdyatm tzqljsdzul (glkbtmfdqa, zayhiltcaa - xfnsbjwewb) View more | - | 19 Oct 2020 | |||
Not Applicable | Malignant Pleural Mesothelioma Second line | 12 | (tpufdqktmw) = dweehprbsq gweodwgsja (wlujzeukvh, 221 - 484) | - | 06 Dec 2016 |